Revelation Biosciences Inc. (REVBW) Financial Statements (2025 and earlier)

Company Profile

Business Address 4660 LAJOLLA VILLAGE DRIVE
SAN DIEGO, CA 92122
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments11,991,7015,252,97978,532537,021
Cash and cash equivalent11,991,7015,252,97978,53211,734
Short-term investments    525,287
Prepaid expense   4,834114,270
Deferred costs 71,13387,171  
Other undisclosed current assets84,69173,132  
Total current assets:12,147,5255,413,28283,366651,291
Noncurrent Assets
Property, plant and equipment65,08490,133  
Asset, held-in-trust   48,302,52173,510,915
Total noncurrent assets:65,08490,13348,302,52173,510,915
TOTAL ASSETS:12,212,6095,503,41548,385,88774,162,206
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,512,3581,539,7022,321,51433,772
Accounts payable1,359,898554,205784,800 
Accrued liabilities1,152,460985,4971,536,71433,772
Derivative instruments and hedges, liabilities   2,390,2583,399,878
Due to related parties✕✕ 774,345 
Other undisclosed current liabilities3,052,5362,911,260  
Total current liabilities:5,564,8944,450,9625,486,1173,433,650
Noncurrent Liabilities
Liabilities, other than long-term debt   2,911,2602,911,260
Deferred revenue   2,911,2602,911,260
Total noncurrent liabilities:   2,911,2602,911,260
Total liabilities:5,564,8944,450,9628,397,3776,344,910
Temporary equity, including noncontrolling interest   47,811,16473,509,325
Equity
Equity, attributable to parent6,647,7151,052,453(7,822,654)(5,692,029)
Common stock2656831,8201,820
Additional paid in capital32,114,55226,398,618  
Accumulated deficit(25,467,102)(25,346,848)(7,824,474)(5,693,849)
Total equity:6,647,7151,052,453(7,822,654)(5,692,029)
TOTAL LIABILITIES AND EQUITY:12,212,6095,503,41548,385,88774,162,206

Income Statement (P&L) (USD)
Annual | Quarterly

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Gross profit:    
Operating expenses(8,656,664)(10,864,511)(3,088,248)(145,492)
Other undisclosed operating income    
Operating loss:(8,656,664)(10,864,511)(3,088,248)(145,492)
Nonoperating income (expense)8,536,41034,962957,845(1,485,008)
Other nonoperating income (expense)207,47334,962957,623(1,485,008)
Interest and debt expense   (41,759) 
Loss from continuing operations:(120,254)(10,829,549)(2,172,162)(1,630,500)
Loss before gain (loss) on sale of properties:✕✕✕(2,172,162)(1,630,500)
Other undisclosed net income   41,537 
Net loss attributable to parent:(120,254)(10,829,549)(2,130,625)(1,630,500)
Preferred stock dividends and other adjustments   (6,896) 
Other undisclosed net income available to common stockholders, basic   2,144,417 
Net income (loss) available to common stockholders, diluted:(120,254)(10,829,549)6,896(1,630,500)

Comprehensive Income (USD)
Annual | Quarterly

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(120,254)(10,829,549)(2,130,625)(1,630,500)
Comprehensive loss, net of tax, attributable to parent:(120,254)(10,829,549)(2,130,625)(1,630,500)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: